These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1291 related items for PubMed ID: 27487187

  • 1. Comparison of the Non-VKA Oral Anticoagulants Apixaban, Dabigatran, and Rivaroxaban in the Extended Treatment and Prevention of Venous Thromboembolism: Systematic Review and Network Meta-Analysis.
    Cohen AT, Hamilton M, Bird A, Mitchell SA, Li S, Horblyuk R, Batson S.
    PLoS One; 2016; 11(8):e0160064. PubMed ID: 27487187
    [Abstract] [Full Text] [Related]

  • 2. Comparison of the Novel Oral Anticoagulants Apixaban, Dabigatran, Edoxaban, and Rivaroxaban in the Initial and Long-Term Treatment and Prevention of Venous Thromboembolism: Systematic Review and Network Meta-Analysis.
    Cohen AT, Hamilton M, Mitchell SA, Phatak H, Liu X, Bird A, Tushabe D, Batson S.
    PLoS One; 2015; 10(12):e0144856. PubMed ID: 26716830
    [Abstract] [Full Text] [Related]

  • 3. Evaluation of oral anticoagulants for the extended treatment of venous thromboembolism using a mixed-treatment comparison, meta-analytic approach.
    Rollins BM, Silva MA, Donovan JL, Kanaan AO.
    Clin Ther; 2014 Oct 01; 36(10):1454-64.e3. PubMed ID: 25092394
    [Abstract] [Full Text] [Related]

  • 4. Effectiveness and Safety of Non-vitamin K Antagonist Oral Anticoagulants for Atrial Fibrillation and Venous Thromboembolism: A Systematic Review and Meta-analyses.
    Almutairi AR, Zhou L, Gellad WF, Lee JK, Slack MK, Martin JR, Lo-Ciganic WH.
    Clin Ther; 2017 Jul 01; 39(7):1456-1478.e36. PubMed ID: 28668628
    [Abstract] [Full Text] [Related]

  • 5. Relative efficacy and safety of non-Vitamin K oral anticoagulants for non-valvular atrial fibrillation: Network meta-analysis comparing apixaban, dabigatran, rivaroxaban and edoxaban in three patient subgroups.
    Lip GY, Mitchell SA, Liu X, Liu LZ, Phatak H, Kachroo S, Batson S.
    Int J Cardiol; 2016 Feb 01; 204():88-94. PubMed ID: 26655548
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Sex related differences in patients with acute venous thromboembolism treated with new oral anticoagulants. A meta-analysis of the interventional trials.
    Loffredo L, Violi F, Perri L.
    Int J Cardiol; 2016 Jun 01; 212():255-8. PubMed ID: 27057930
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Comparative efficacy and safety of anticoagulants and aspirin for extended treatment of venous thromboembolism: A network meta-analysis.
    Sobieraj DM, Coleman CI, Pasupuleti V, Deshpande A, Kaw R, Hernandez AV.
    Thromb Res; 2015 May 01; 135(5):888-96. PubMed ID: 25795564
    [Abstract] [Full Text] [Related]

  • 10. The risk of gastrointestinal hemorrhage with non-vitamin K antagonist oral anticoagulants: A network meta-analysis.
    Oh HJ, Ryu KH, Park BJ, Yoon BH.
    Medicine (Baltimore); 2021 Mar 19; 100(11):e25216. PubMed ID: 33726018
    [Abstract] [Full Text] [Related]

  • 11. Dabigatran, rivaroxaban and apixaban for extended venous thromboembolism treatment: network meta-analysis.
    Alotaibi G, Alsaleh K, Wu C, Mcmurtry MS.
    Int Angiol; 2014 Aug 19; 33(4):301-8. PubMed ID: 25056161
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Safety ad efficacy of direct oral anticoagulants for extended treatment of venous thromboembolism.
    Imberti D, Pomero F, Benedetti R, Fenoglio L.
    Intern Emerg Med; 2016 Oct 19; 11(7):895-900. PubMed ID: 27550399
    [Abstract] [Full Text] [Related]

  • 16. Phase III trials of new oral anticoagulants in the acute treatment and secondary prevention of VTE: comparison and critique of study methodology and results.
    Cohen AT, Imfeld S, Rider T.
    Adv Ther; 2014 May 19; 31(5):473-93. PubMed ID: 24821599
    [Abstract] [Full Text] [Related]

  • 17. Effectiveness and safety of reduced dose non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study.
    Nielsen PB, Skjøth F, Søgaard M, Kjældgaard JN, Lip GY, Larsen TB.
    BMJ; 2017 Feb 10; 356():j510. PubMed ID: 28188243
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Cost-effectiveness of Apixaban Versus Other Oral Anticoagulants for the Initial Treatment of Venous Thromboembolism and Prevention of Recurrence.
    Lanitis T, Leipold R, Hamilton M, Rublee D, Quon P, Browne C, Cohen AT.
    Clin Ther; 2016 Mar 10; 38(3):478-93.e1-16. PubMed ID: 26922297
    [Abstract] [Full Text] [Related]

  • 20. Oral anticoagulants for primary prevention, treatment and secondary prevention of venous thromboembolic disease, and for prevention of stroke in atrial fibrillation: systematic review, network meta-analysis and cost-effectiveness analysis.
    Sterne JA, Bodalia PN, Bryden PA, Davies PA, López-López JA, Okoli GN, Thom HH, Caldwell DM, Dias S, Eaton D, Higgins JP, Hollingworth W, Salisbury C, Savović J, Sofat R, Stephens-Boal A, Welton NJ, Hingorani AD.
    Health Technol Assess; 2017 Mar 10; 21(9):1-386. PubMed ID: 28279251
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 65.